Fizz away colds and flu with newly-launched Cepacol raspberry effervescent
This combination product is crafted to help ease sore throats, assist with nasal congestion, control sneezing, and calm coughs
When cold and flu symptoms strike, the newly launched Cepacol Effervescent in refreshing Raspberry flavour is your fizzy ally.
This combination product is crafted to help ease sore throats, assist with nasal congestion, control sneezing, and calm coughs. By opening airways and thinning mucus, it helps provide comfort from chesty coughs linked to airway inflammation1c.
Beyond that, Cepacol Effervescent assists in bolstering the immune function in the upper respiratory tract and offers antioxidant benefits to help maintain overall health. It contains immune-boosting vitamin A (vitamin A acetate), vitamin C (ascorbic acid) and vitamin D3 (cholecalciferol), along with zinc, to support your body's defences. Pelargonium sidoides (African geranium) is included for the symptomatic treatment of the common cold, and ivy leaf extract serves as an expectorant to assist with productive coughs.
So, when you're dealing with cold and flu symptoms, remember, there's a Cepacol for that!
For more information, visit www.cepacol.co.za and join the conversation on Facebook.
Cepacol Effervescent — approximate recommended selling price (RSP) is R125.95 for a pack of 10 and R169.95 for a pack of 20. Cepacol's range of products is available at leading pharmacies and retailers nationwide.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
IOL News
2 days ago
- IOL News
University of Cape Town leads regional action plan against drug-resistant malaria in East Africa
UCT is part of a research consortium that has played a pivotal role in developing the first regional action plan to combat drug-resistant malaria in East Africa. Image: Pexels/Jimmy Chan A research consortium led by the University of Cape Town (UCT) has played a pivotal role in developing the first regional action plan to combat drug-resistant malaria in East Africa. Endorsed by health ministers from across the region, the plan represents a major step forward in preserving the efficacy of life-saving antimalarial treatments. The Regional Detailed Action Plan for Responding to Antimalarial Drug Resistance in East Africa was officially endorsed in May 2025 at the 25th Ordinary Meeting of the East African Community (EAC) Sectoral Council of Ministers of Health. Developed through a partnership between UCT's Mitigating Antimalarial Resistance Consortium in South-East Africa (MARC SE-Africa) and the EAC Roll Back Malaria Secretariat, the plan unites national malaria programmes and global health stakeholders behind a common goal: safeguarding effective malaria treatment amid growing resistance and tightening global funding. Senior researcher at UCT and technical advisor within the consortium, Dr Stephanie van Wyk, said: 'This is a landmark achievement. This endorsement reflects the potential realised when scientific evidence, political will and regional solidarity converge. UCT remains committed to fostering solutions that not only assist our East African neighbours but also provide a template for responses to drug resistant malaria in other African regions. By enhancing case management and proactively addressing resistance challenges through regional collaboration, we contribute to safeguarding the effectiveness of antimalarial treatments throughout the endemic regions of Southern Africa.' The action plan targets drug-resistant Plasmodium falciparum, especially resistance to artemisinin-based combination therapies (ACTs) – the frontline treatment for malaria.– the frontline treatment for malaria. The plan outlines a roadmap for optimised treatment protocols, improved supply chain management and strengthened regional cooperation by integrating the latest research and surveillance data. It also identifies evidence-based short- and medium-term interventions to address resistance before it undermines decades of progress in malaria control. Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Next Stay Close ✕ The plan's development involved intensive collaboration with leading national and international health partners, including the Global Fund, the President's Malaria Initiative, the Clinton Health Access Initiative, the African Leaders Malaria Alliance and Medicines for Malaria Venture. The EAC Roll Back Malaria Secretariat, led by Dr Michael Katende, played a central coordinating role in aligning partner countries and institutions behind a shared vision. 'Malaria knows no borders, and neither should our response. This consensus-based regional action plan demonstrates the power of multinational collaboration in tackling drug-resistant malaria. Now is the critical moment for East African nations and international partners to commit to sustained action and ensure effective malaria treatment remains available for millions at risk,' said Professor Karen Barnes, lead of MARC SE-Africa and coordinator of the initiative at UCT. With more than 300 million people – over 80% of the EAC population – living at risk of malaria, the plan arrives at a critical juncture. Resistance is rising, and funding shortfalls threaten to reverse hard-won gains. The coordinated approach signals a shift toward African-led, research-driven and politically unified responses to one of the continent's most pressing public health threats. Through this regional initiative, East Africa sets a new precedent for protecting the impact of ACTs, reinforcing its commitment to collective action, and demonstrating leadership in global health innovation.
The South African
4 days ago
- The South African
Fizz away colds and flu with newly-launched Cepacol® Raspberry effervescent
When cold and flu symptoms strike, the newly launched Cepacol® Effervescent in refreshing Raspberry flavour is your fizzy ally. This combination product is crafted to help ease sore throats, assist with nasal congestion, control sneezing, and calm coughs. By opening airways and thinning mucus, it helps provide comfort from chesty coughs linked to airway inflammation. Helps maintain overall health Beyond that, Cepacol® Effervescent assists in bolstering the immune function in the upper respiratory tract and offers antioxidant benefits to help maintain overall health. It contains immune-boosting vitamin A (vitamin A acetate), vitamin C (ascorbic acid) and vitamin D3 (cholecalciferol), along with zinc, to support your body's defences. Pelargonium sidoides (African geranium)is included for the symptomatic treatment of the common cold, and ivy leaf extract serves as an expectorant to assist with productive coughs. So, when you're dealing with cold and flu symptoms, remember, there's a Cepacol® for that! For more information, visit and join the conversation on Facebook. Cepacol® Effervescent – approx. RSP for 10's: R125.95 and 20's: R169.95. Cepacol®'s range of products is available at leading pharmacies and retailers nationwide. Let us know by leaving a comment below, or send a WhatsApp to 060 011 021 1 Subscribe to The South African website's newsletters and follow us on WhatsApp, Facebook, X and Bluesky for the latest news.
IOL News
4 days ago
- IOL News
Life Healthcare Group reports 10. 5% rise in interim divided and plans expansion
Life Healthcare Group, which reported strong operational results for the six months to March 31, 2025 from its network of private hospitals and other healthcare facilities, said the disposal of its Life Molecular Imaging business was expected to be finalised in the second half. Image: Supplied Life Healthcare Group lifted its interim dividend by 10.5% to 21 cents a share in the six months to March 31, and it intends to continue growing its underlying asset base significantly in Southern Africa during the second half. The group, which operates 64 healthcare facilities across South Africa and Botswana, plans to add 58 acute hospital beds and 24 acute rehabilitation beds, and it will start building the new 140-bed Life Paarl Valley Hospital in the Western Cape. A new cath-lab and a new vascular lab will also be added to the acute business, as stated by CEO Peter Wharton-Hood in the results statement. The group will continue to grow its diagnostics business, with further transactions expected to be completed in the second half, as well as the addition of two new PET-CT sites. 'The southern African business will look to drive occupancies to 70%, with paid patient days (PPD) growth expected to be 1.5%. The southern African business will continue to optimise its asset portfolio and focus on operational efficiencies,' he said. Capital expenditure for the 2025 year is expected to be R2.3 billion. The R13.9bn Life Molecular Imaging (LMI) disposal to Lantheus Holdings is also expected to close in the second half. In the six-month period under review, there has been robust activity growth, with paid patient days (PPDs) up by 2% and occupancy at 68.6%. Revenue from continuing operations increased by 8.1% to R12.1bn. Normalised earnings per share increased by 9.1% to 49 cents. Earnings per share (continuing and discontinued operations) decreased to negative 155.2 cents from 242.8 positive cents in the first half of 2024, mainly due to the R2.8bn one-off gain in the first half of 2024 following the completion of the Alliance Medical Group disposal, and a R2.9bn fair value loss on the Piramal contingent consideration in the first half of 2025. The group remains in a strong financial position. As of March 31, 2025, net debt to normalised EBITDA (earnings before interest, tax, depreciation, and amortisation) of 0.65 times is well within the covenant of 3.5 times. Cash from continuing operations was R2bn and represented 105.3% of normalised EBITDA from continuing operations. The strong operating performance for the six-month period, with revenue up by 8.1%, was driven by 'robust activity growth,' benefits from acquisitions concluded in the second half of 2024, and a tariff increase. The acute hospitals delivered strong revenue growth in the period, with PPDs growing by 2% on a like-for-like basis. This translated into a higher occupancy of 68.3% compared to 66.2% in the prior period. The acute hospitals had a strong second quarter, with occupancies over 71%, benefiting from the timing of the Easter and school holidays. Visit:
